Financial Performance - The company's total revenue for 2021 was ¥527,440,662.01, representing a decrease of 50.82% compared to ¥1,072,399,917.76 in 2020[22] - The net profit attributable to shareholders for 2021 was -¥22,762,007.90, a significant decline from a profit of ¥98,067,613.55 in 2020[22] - The net cash flow from operating activities was -¥84,252,019.54, compared to ¥154,122,592.63 in the previous year, indicating a substantial decrease in operational cash generation[22] - The company's operating revenue for 2021 was CNY 527.44 million, a decrease of CNY 544.96 million compared to the previous year[31] - The net profit attributable to shareholders of the parent company was CNY -22.76 million, a decrease of CNY 120.83 million year-on-year[31] - Basic earnings per share were CNY -0.0778, down from CNY 0.3426 in 2020[24] - The weighted average return on equity was -3.42%, a decrease of 19.43 percentage points compared to 2020[24] - The company reported a gross margin of 20.71%, down 13.16 percentage points from the previous year[70] Shareholder and Governance - The company plans not to distribute profits or increase capital reserves for 2021 due to the negative net profit situation[4] - The company has a three-year shareholder return plan in place, which will be considered in future profit distribution decisions[4] - The company held 5 shareholder meetings and 12 board meetings during the reporting period to strengthen corporate governance[31] - The company emphasizes investor relations, maintaining communication with shareholders and stakeholders to protect their interests and enhance corporate value[147] - The company adheres to strict information disclosure practices, ensuring transparency and compliance with relevant regulations[148] - The company has a cash dividend policy that stipulates a minimum of 25% of distributable profits must be distributed as cash dividends when conditions allow[173] Risk Management - The company has not identified any significant risks that could materially affect its operations during the reporting period[7] - The company is facing risks from intensified market competition and potential changes in industry regulations that could impact its operations[132][133] - The company faces risks from changes in the overseas market environment, which may adversely affect its operations due to political, economic, and trade policy factors[134] - Fluctuations in exchange rates could impact the company's performance, particularly as export revenues are primarily settled in USD and EUR, with potential adverse effects if the RMB experiences significant volatility[135] Research and Development - The company invested CNY 30.623 million in R&D during the reporting period, a decrease of 9.83% compared to the previous year, focusing on new topical formulations and transdermal drug delivery technologies[34] - The company emphasizes technology research and development as a key competitive advantage, focusing on transdermal drug delivery technology improvements and stem cell-based tissue regeneration[59] - The company has established a "New Transdermal Preparation Research Center" in collaboration with Zhejiang University to enhance its R&D capabilities[59] - The company added 4 invention patents and 9 utility model patents during the reporting period, totaling 11 invention patents and 33 utility models[95] Product Development and Market Strategy - The company plans to expand its product line by adding a high-end medical glove production line, particularly focusing on nitrile gloves, which have shown rapid growth in the market[35] - The company is focusing on expanding its nitrile glove production capacity, which is expected to enhance market competitiveness[89] - The company is committed to improving its product offerings in the medical supplies sector, including various types of adhesive bandages and medical gloves[92] - The company is exploring the development of solvent-free medical adhesives and improving transdermal drug delivery technologies[97] Operational Efficiency - The company has a procurement model based on "sales-driven ordering," ensuring raw materials are sourced according to production orders[54] - The production model is "sales-driven production," allowing the company to adapt to customer demands and maintain service quality for large clients[55] - The company has a management team with extensive experience and a structured management system covering all operational aspects[62] - The company is committed to maintaining product quality and reducing production costs through improved procurement and supplier management[34] Environmental and Social Responsibility - The company has implemented measures to prevent water pollution, including a rainwater drainage system and proper disposal of hazardous waste[184] - The company actively engages in clean production practices and regularly maintains its environmental facilities to comply with national regulations[186] - The company has established a social responsibility management system, emphasizing a people-oriented approach and continuous improvement[188] - Employee wages have been steadily increased, with the company providing social insurance and housing funds for all employees[188] Financial Management - The company has successfully reduced its debt levels, improving its financial stability and credit rating[152] - The company is committed to optimizing its resource allocation and improving financial management to reduce costs and enhance profitability[128] - The company is seeking long-term partnerships with strategic suppliers and sales channels to build a stable production and sales integration[129] Strategic Partnerships and Acquisitions - The company is expanding its business into the cosmetics sector through a partnership with Shanghai Meilianni Cosmetics Co., transferring all related business qualifications and assets[198] - South Health Co. acquired 60% equity of Meilinni Bio from Shanghai Meilinni Cosmetics Co., with a transfer price of 12.8 million yuan based on financial status and future performance forecasts[200]

2021 年第三季度报告 证券代码：603880 证券简称：南卫股份 江苏南方卫材医药股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人李平、主管会计工作负责人项琴华及会计机构负责人（会计主管人员）王亚华保 证季度报告中财务报表信息的真实、准确、完整。 第三季度财务报表是否经审计 一、 主要财务数据 主要会计数据和财务指标 1 / 12 单位：元 币种：人民币 项目 本报告期 本报告期 比上年同 期增减变 动幅度(%) 年初至报告期末 年初至报告期 末比上年同期 增减变动幅度 (%) 营业收入 142,882,982.40 -21.26 405,253,231.61 -55.49 归属于上市公司股东的 净利润 3,522,074.22 -46.62 14,738,567.26 -83.96 归属于上市公司股东的 ...

Financial Performance - The company's operating revenue for the first half of 2021 was ¥262,370,249.21, a decrease of 64.01% compared to ¥729,093,174.95 in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2021 was ¥11,216,493.04, down 86.52% from ¥83,215,991.64 in the previous year[19]. - The net cash flow from operating activities was -¥30,602,512.86, a decline of 121.60% compared to ¥141,696,341.32 in the same period last year[19]. - Basic earnings per share for the first half of 2021 were ¥0.038, down 86.62% from ¥0.284 in the same period last year[20]. - The weighted average return on net assets decreased by 12.25 percentage points to 1.60% from 13.85% in the previous year[20]. - The company reported a significant decline in net profit after deducting non-recurring gains and losses, with a decrease of 91.79% to ¥0.023 per share[20]. - The company's operating revenue decreased due to a reduction in sales of epidemic prevention protective products[21]. - Net profit attributable to shareholders of the listed company decreased primarily due to the decline in operating revenue[21]. - Earnings per share decreased mainly due to the reduction in net profit attributable to shareholders of the listed company[21]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,216,831,313.95, an increase of 13.44% from ¥1,072,645,455.80 at the end of the previous year[19]. - The net assets attributable to shareholders decreased by 1.66% to ¥685,204,456.67 from ¥696,791,263.63 at the end of the previous year[19]. - Total liabilities reached CNY 526,359,635.07, compared to CNY 371,840,580.60, showing an increase of around 41.5%[129]. - Short-term borrowings surged to CNY 321,796,260.00 from CNY 177,624,500.00, representing an increase of approximately 81.0%[129]. Research and Development - The company invested RMB 13.91 million in R&D, an increase of 26.56% compared to the same period last year, focusing on new external preparations and transdermal delivery technology[46]. - The company has developed a strong technical research and development capability, leading in technologies such as adhesive perforation and high water absorption hydrogel preparation[38]. - The company has established a collaborative research platform with Zhejiang University, focusing on transdermal drug delivery technologies and micro-needle drug delivery systems[39]. Market Position and Strategy - The company has established a strong market position as a leading medical device manufacturer in China, leveraging over 30 years of operational experience and the cluster effect of the textile industry in the Yangtze River Delta region[37]. - The company primarily operates under an ODM model, while also increasing the development and market expansion of its own brand products, including first aid kits, sports protection products, and protective gear[35]. - The company is actively pursuing international markets, but faces risks from geopolitical and economic factors that could impact its operations[69]. - The company is exploring potential mergers and acquisitions to strengthen its market position[153]. Compliance and Governance - The company has obtained GMP certification and relevant production licenses, ensuring compliance with national quality management standards for medical devices[71]. - The company emphasizes compliance with the Company Law and Securities Law in all share repurchase and purchase activities[90]. - The company has passed resolutions to revise governance documents, reflecting ongoing improvements in corporate governance practices[76]. Environmental and Social Responsibility - The company has implemented measures for wastewater management, including connecting domestic wastewater to the local sewage treatment plant[82]. - The company has established solid waste disposal protocols, with hazardous waste managed by qualified units[84]. - The company has developed an emergency response plan for environmental incidents, enhancing its emergency management capabilities[84]. Shareholder Commitments and Stock Management - The company’s controlling shareholder, Li Ping, committed to purchasing company shares at a price not exceeding 110% of the latest audited net asset value per share, with a minimum purchase of 3% of total shares within 90 days of the announcement[90]. - The company plans to issue convertible bonds, which may enhance its capital structure and provide funding for future projects[77]. - The company has established a three-year shareholder return plan for 2021-2023, aiming to enhance shareholder value[77]. Legal and Regulatory Risks - The company is subject to regulatory risks due to the high level of government oversight in the pharmaceutical manufacturing industry[67]. - The company is involved in multiple significant lawsuits related to sales contract disputes with various entities, including Jiangsu Hantang International Trade Co., Ltd. and Shenzhen Xinhongmei Medical Equipment Co., Ltd.[99]. - The company has a pending lawsuit against Shen Yuzhong regarding a compensation amount of 602.17 thousand yuan, which is based on performance compensation from a share transfer agreement[101]. Future Outlook - Future performance guidance indicates a cautious outlook, with expectations of moderate growth in the upcoming quarters[153]. - The company plans to continue expanding its market presence and product offerings in the medical supplies sector[162].

2021 年第一季度报告 公司代码：603880 公司简称：南卫股份 江苏南方卫材医药股份有限公司 2021 年第一季度报告 1 / 19 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 6 | | 四、 | 附录 9 | 2021 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 3 / 19 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人李平、主管会计工作负责人项琴华及会计机构负责人（会计主管人员）王亚华保 证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 2021 年第一季度报告 单位：元 币种：人民币 | 项目 | 本期金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益 | | | | 越权审批，或无正式批准文件，或偶发性的税收返还、减免 | | | | 计入当期损益的政 ...

2020 年年度报告 六、 前瞻性陈述的风险声明 √适用 □不适用 公司代码：603880 公司简称：南卫股份 江苏南方卫材医药股份有限公司 2020 年年度报告 1 / 197 2020 年年度报告 重要提示 三、 立信会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人李平、主管会计工作负责人项琴华及会计机构负责人（会计主管人员）王亚华声 明：保证年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 公司2020年年度拟以实施权益分派股权登记日登记的总股本为基数分配利润及资本公积金转 增股本。上市公司拟向全体股东每10股派发现金红利1.5元（含税），截至2020年12月31日，公司 总股本225,180,000股，以此计算合计拟派发现金红利33,777,000.00元（含税）。同时拟以资本 公积金每10股转增3股。本次转股后，公司的总股本为292,734,000股。 以上利润分配预案尚需公司2020年年度股东大会审议通过。 本报告所涉及的未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质承诺，请投 资者注意风险。 七、 ...

| 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 9 | 2020 年第三季度报告 公司代码：603880 公司简称：南卫股份 江苏南方卫材医药股份有限公司 2020 年第三季度报告 1 / 22 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | 本报告期末比上年 度末增减(%) | | | --- | --- | --- | --- | --- | | 总资产 | 1,092,792,218.71 | 869,601,971.34 | | 25.67 | | 归属于上市公司股东的净 | 646,764,332.76 | 564,157,337.40 | | 14.64 | | 资产 | | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减 | | | | （1-9 月） | （1-9 月） | (%) | | | 经营活动产生的现金流量 | 141,031,803.96 | 6,559,6 ...

2020 年半年度报告 公司代码：603880 公司简称：南卫股份 江苏南方卫材医药股份有限公司 2020 年半年度报告 1 / 147 2020 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人李平、主管会计工作负责人项琴华及会计机构负责人（会计主管人员）王亚华声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质承诺，请投 资者注意风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 重大风险提示 报告期内，不存在对公司生产经营产生实质性影响的特别重大风险。公司已在本报告中详细 描述公司在生产经营过程中可能存在的相关风险，详见本报告第四节" ...

2020 年第一季度报告 公司代码：603880 公司简称：南卫股份 江苏南方卫材医药股份有限公司 2020 年第一季度报告 1 / 18 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 6 | | 四、 | 附录 8 | 2020 年第一季度报告 一、 重要提示 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 3 / 18 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度 末增减(%) 总资产 898,068,339.05 869,601,971.34 3.27 归属于上市公司股东的 净资产 572,752,554.44 564,157,337.40 1.52 年初至报告期末 上年初至上年报告期末 比上年同期增减(%) 经营活动产生的现金流 量净额 -6,076,249.05 11,284,653.07 -153.85 年初至报告期末 上年初至上年报告期末 比上年同期增减（%） 营业收入 100,435,111.68 100,510,945.78 -0.08 归属于上市公司股东的 净利润 ...

重要提示 2019 年年度报告 公司代码：603880 公司简称：南卫股份 江苏南方卫材医药股份有限公司 2019 年年度报告 1 / 186 2019 年年度报告 否 三、 立信会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 八、 是否存在违反规定决策程序对外提供担保的情况？ 四、 公司负责人李平、主管会计工作负责人项琴华及会计机构负责人（会计主管人员）王亚华声 明：保证年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 公司2019年年度拟以实施权益分派股权登记日登记的总股本为基数分配利润及资本公积金转 增股本。上市公司拟向全体股东每10股派发现金红利0.5元（含税），截至2019年12月31日，公司 总股本169,000,000股，以此计算合计拟派发现金红利8,450,000元（含税）。同时拟以资本公积 金每10股转增3股。本次转股后，公司的总股本为219,700,000股。 以上利润分配预案尚需公司2019年年度股东大会审议通过。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的未来计划、发展战略等前瞻性陈述，不构成公司 ...

2019 年第三季度报告 公司代码：603880 公司简称：南卫股份 江苏南方卫材医药股份有限公司 2019 年第三季度报告 1 / 21 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 8 | 2019 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人李平、主管会计工作负责人项琴华及会计机构负责人（会计主管人员）王亚华保 证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | 本报告期末比上年度 | | --- | --- | --- | --- | | | | | 末增减(%) | | 总资产 | 802,378,421 ...